A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 16, 2028

Study Completion Date

June 16, 2028

Conditions

Solid Tumors With FGFR2 Alterations, Adult

Interventions

DRUG

3HP-2827

3HP-2827 will be administered orally once daily in 28-day cycles.

Trial Locations (2)

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

ZhongShan Hospital, Shanghai

All Listed Sponsors

lead

3H (Suzhou) Pharmaceuticals Co., Ltd.

INDUSTRY